Biotechnology Healthcare - June 2008 - (Page 11) New CIMZIA is now available for your members with moderate to severe Crohn’s disease. CIMZIA is indicated for reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis and other serious infections. Please see Important Safety Information and Brief Summary of full Prescribing Information on adjacent pages. http://www.cimzia.com/
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.